Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) - Total Liabilities

Latest as of June 2025: CN¥211.52 Million CNY ≈ $30.95 Million USD

Based on the latest financial reports, Suzhou Fushilai Pharmaceutical Co. Ltd. (301258) has total liabilities worth CN¥211.52 Million CNY (≈ $30.95 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Suzhou Fushilai Pharmaceutical Co. Ltd. to evaluate the company's liquid asset resilience ratio.

Suzhou Fushilai Pharmaceutical Co. Ltd. - Total Liabilities Trend (2019–2024)

This chart illustrates how Suzhou Fushilai Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Suzhou Fushilai Pharmaceutical Co. Ltd. assets under control.

Suzhou Fushilai Pharmaceutical Co. Ltd. Competitors by Total Liabilities

The table below lists competitors of Suzhou Fushilai Pharmaceutical Co. Ltd. ranked by their total liabilities.

Company	Country	Total Liabilities
Xuancheng Valin Precision Technology Co Ltd SHG:603356	China	CN¥884.37 Million
Byggmax Group AB ST:BMAX	Sweden	Skr3.40 Billion
Baader Bank Aktiengesellschaft F:BWB	Germany	€4.09 Billion
Nanjing Chervon Auto Precision Technology Co Ltd SHG:603982	China	CN¥4.33 Billion
Zilltek Technology Corp TWO:6679	Taiwan	NT$735.95 Million
PharmaSGP Holding SE F:PSG	Germany	€81.51 Million
Top Bright Holding Co Ltd TW:8499	Taiwan	NT$4.07 Billion
Bell Financial Group Ltd AU:BFG	Australia	AU$866.82 Million

Liability Composition Analysis (2019–2024)

This chart breaks down Suzhou Fushilai Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Suzhou Fushilai Pharmaceutical Co. Ltd. balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	10.37	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.10	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suzhou Fushilai Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suzhou Fushilai Pharmaceutical Co. Ltd. (2019–2024)

The table below shows the annual total liabilities of Suzhou Fushilai Pharmaceutical Co. Ltd. from 2019 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥200.84 Million ≈ $29.39 Million	+17.83%
2023-12-31	CN¥170.45 Million ≈ $24.94 Million	-19.50%
2022-12-31	CN¥211.75 Million ≈ $30.99 Million	-6.91%
2021-12-31	CN¥227.47 Million ≈ $33.29 Million	+37.35%
2020-12-31	CN¥165.61 Million ≈ $24.23 Million	-2.28%
2019-12-31	CN¥169.48 Million ≈ $24.80 Million	--

About Suzhou Fushilai Pharmaceutical Co. Ltd.

SHE:301258 China Biotechnology

Market Cap

$331.60 Million

CN¥2.27 Billion CNY

Market Cap Rank

#14452 Global

#4319 in China

Share Price

CN¥24.72

Change (1 day)

+0.12%

52-Week Range

CN¥21.91 - CN¥37.35

All Time High

CN¥63.49